According to an article from Globe Newswire, the company Shire plc recently presented new data in relation to recombinant human parathyroid hormone (rhPTH) and its relationship to hypoparathyroidism. This information touched on subjects such as the extent of symptoms experienced by patients with chronic hypoparathyroidism as well as measuring the impact the currently available treatments have. Hypoparathyroidism is considered chronic if the patient display reduced calcium levels and PTH levels for a period of six months or greater.
Chronic hypoparathyroidism is a very rare condition in which the functionality of the parathyroid glands is impaired due to the insufficient production of the parathyroid hormone. A significant outcome of this decreased function is reduced levels of calcium in the blood. Symptoms include an unusual tingling sensation around the mouth, hands, and feet called paresthesia. Other symptoms include cramps and muscle spasms of the hands and feet, insomnia, bone pain, fatigue, and headaches. Low calcium levels can cause dangerous health events, such as irregular heartbeat, spasms affecting the airway, and seizures. Hypoparathyroidism has multiple causes; it can be inherited, but immune system damage, parathyroid surgery, and magnesium deficiency can also be responsible. Treatment typically involves calcium, vitamin D, and parathyroid hormone supplementation. To learn more about hypoparathyroidism, click here.
The company presented data the emphasized the value of recombinant parathyroid hormone supplementation. Overall, patients that were regularly getting the supplement retained better kidney function in comparison to those that did not. Shire presented multiple studies focused on hypoparathyroidism, highlighting the company’s commitment to understanding this rare condition more thoroughly.
